Interview: AstraZeneca ‘Is More Than Oncology’

AZ’s BioPharma Unit Head Points To CVRM And Respiratory Promise

28 Oct 2019

• By Sten Stovall

Ruud Dobber oversees AstraZeneca’s biopharmaceuticals division, which generates some 40% of group total revenues. He tells Scrip to “Watch this space.”

Three_Pipes — AstraZeneca’s Three Therapy Areas Are Cancer, CVRM and Respiratory • Source: Shutterstock

While clearly enjoying the rewards of its a strengthening oncology portfolio, AstraZeneca PLC also used its third-quarter results update 24 October to stress that its two other therapeutic pillars - respiratory and CVRM - are performing well and hold great promise.

“Yes, we are very proud of our oncology performance at AstraZeneca, but equally we’re trying to signal that AstraZeneca is...